Keudell Morrison Wealth Management Purchases 28 Shares of argenex SE $ARGX

Keudell Morrison Wealth Management grew its position in argenex SE (NASDAQ:ARGX) by 5.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 534 shares of the company’s stock after acquiring an additional 28 shares during the quarter. Keudell Morrison Wealth Management’s holdings in argenex were worth $294,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Rakuten Securities Inc. lifted its position in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock worth $36,000 after acquiring an additional 22 shares during the period. WPG Advisers LLC bought a new stake in shares of argenex in the 1st quarter worth approximately $37,000. Golden State Wealth Management LLC bought a new stake in shares of argenex in the 1st quarter worth approximately $44,000. Brooklyn Investment Group lifted its position in shares of argenex by 102.7% in the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 38 shares during the period. Finally, Banque Transatlantique SA bought a new stake in shares of argenex in the 1st quarter worth approximately $62,000. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on ARGX shares. Stifel Nicolaus set a $882.00 price objective on argenex in a research report on Thursday, September 18th. Truist Financial increased their target price on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a report on Monday, September 15th. Piper Sandler increased their target price on argenex from $750.00 to $820.00 and gave the stock an “overweight” rating in a report on Tuesday, August 26th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Saturday, September 27th. Finally, Wedbush reissued an “outperform” rating and issued a $800.00 target price on shares of argenex in a report on Monday, August 25th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $802.90.

argenex Trading Up 1.1%

ARGX stock opened at $800.00 on Friday. The business’s 50-day moving average price is $702.97 and its two-hundred day moving average price is $621.08. The firm has a market cap of $48.96 billion, a PE ratio of 41.03, a P/E/G ratio of 0.87 and a beta of 0.46. argenex SE has a 1-year low of $510.05 and a 1-year high of $803.74.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. On average, analysts forecast that argenex SE will post 3.13 earnings per share for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.